Psychosis and BPD have previously been linked to persistent nightmares in childhood, and these findings highlight the importance of confronting sleep disturbances at young ages.
Melatonin and other melatonin receptor agonists have demonstrated efficacy in the treatment of circadian rhythm disorders in both pediatric and adult populations.
Only 65.2% of adults surveyed in United States in 2014 reported that they consistently get at least 7 hours of sleep each night.
Maintaining a consistent sleep-wake schedule, including exposure to bright light in the morning and avoidance of it at night, may be the most reliable way to reduce pandemic-induced sleep problems.
Individuals most at risk for neurobehavioral performance impairment during sleep deprivation can be accurately identified by a visual psychomotor vigilance task.
Approximately 20% of women experienced an increase in sleep issues during the presurgery period, although for the majority of women sleep trajectories were generally stable pre- and postsurgery.
Women with insomnia were more likely to report prior or current depression than women without insomnia in the study.
Researchers found that a poor night’s sleep may increase risk for migraine the following day, rather than the next morning.
The Drug Enforcement Agency (DEA) has designated Sunosi (solriamfetol; Jazz Pharmaceuticals) a Schedule IV controlled substance.
A recently published systematic review investigated the benefits and risks of melatonin supplementation for pediatric patients with sleep disturbances.
